{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.21","value":"1274.30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"PK was analyzed only when all patients has completed 12 cycles of treatment or discontinued the study treatment early.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.","id":"OG000","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetics Analysis Set (PAS): All patients with at least one evaluable PK blood sample.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 8","title":"Pharmacokinetics: Steady State Concentration of Nilotinib in Newly Diagnosed CML-CP Patients","type":"SECONDARY","unitOfMeasure":"ng/mL"}